Mizuho raised the firm’s price target on CVS Health (CVS) to $76 from $70 and keeps an Outperform rating on the shares. The firm surveyed 215 physicians over 13 specialties to gauge hospital inpatient and outpatient trends during Q1. The survey suggests both inpatient and outpatient growth trends, while still elevated, appear to have peaked, the analyst tells investors in a research note. Mizuho views the survey as positive for managed care and clinical labs and neutral for hospitals.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- Macro Headwind-Immune CVS Health Stock Set to Extend 50% YTD Rally
- 3 ‘Strong Buy’ Stocks to Consider as Tariffs Push S&P 500 (SPX) Toward Bear Market
- Early notable gainers among liquid option names on April 8th
- CVS Health Stock Soars on Leadership Changes
- Morning Movers: Stock futures rebound following days of dips